Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06807294 · ClinicalTrials.gov registry record · NA

Feasibility Testing of a Tai Chi Program for Chemotherapy-Induced Peripheral Neuropathy Treatment (TCT)

A NA study of Neuropathy and Peripheral Neuropathy Due to Chemotherapy, sponsored by Dana-Farber Cancer Institute.

Recruiting
Registry status
NA
Development phase
21
Enrollment target
1
Study location

NCT06807294 is a NA study of Neuropathy and Peripheral Neuropathy Due to Chemotherapy that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 21 participants, below the 186-participant average among 22 other Neuropathy trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06807294, a NA study of Neuropathy and Peripheral Neuropathy Due to Chemotherapy, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.

RECRUITING
Registry status
NA
Development phase
21 participants
Enrollment target
1
Study location

Study Summary

This research is being done to determine whether a 12-week virtual Tai Chi training program, designed to improve balance and small nerve fiber function, is feasible and acceptable among cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN).

Interventions

  • BEHAVIORAL Tai Chi Program

Study Locations (1)

Massachusetts

  • Dana-Farber Cancer Institute - Boston

Trial Details

FieldValue
Enrollment Target 21 participants
Start Date 2026-01-16
Est. Completion 2026-10-31
Phase NA

Sponsor

Dana-Farber Cancer Institute

781 total trials

What the Registry Record Tells You About NCT06807294

The ClinicalTrials.gov registry entry for NCT06807294 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 186-participant average among 22 other Neuropathy trials with a reported enrollment target (89% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Neuropathy appearing as the primary indexed condition, and to 1 intervention - of which Tai Chi Program is the first listed.

NCT06807294 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06807294 about?

NCT06807294 is a clinical study titled "Feasibility Testing of a Tai Chi Program for Chemotherapy-Induced Peripheral Neuropathy Treatment (TCT)". This research is being done to determine whether a 12-week virtual Tai Chi training program, designed to improve balance and small nerve fiber function, is feasible and acceptable among cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN).

What is the current status of trial NCT06807294?

This trial is currently recruiting. It is a NA study. The enrollment target is 21 participants. The study started on 2026-01-16. Estimated completion is 2026-10-31.

What conditions does trial NCT06807294 study?

This clinical trial studies the following conditions: Neuropathy, Peripheral Neuropathy Due to Chemotherapy, Peripheral Neuropathies, Chemotherapy Induced Peripheral Neuropathy (CIPN).

What interventions are being tested in trial NCT06807294?

The interventions under investigation include: Tai Chi Program (BEHAVIORAL).

Who is sponsoring clinical trial NCT06807294?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06807294 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Neuropathy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.